ABSTRACT
3 beta-Hydroxy-5 alpha-cholest-8(14)-en-15-one (I) is a potent regulator of cholesterol metabolism. In the present study, the 7 alpha-methyl-25,26,26,26,27,27,27-heptafluoro analog (X) of I has been synthesized with the goal of blocking not only the side chain oxidation of I but also its conversion to cholesterol. X was prepared in seven steps from the known 7 alpha-methyl analog (IX) of I. Treatment of the acetate of IX with a mixture of trifluoroacetic anhydride, hydrogen peroxide, and sulfuric acid gave 3 beta-acetoxy-7 alpha-methyl-24-hydroxy-5 alpha-chol-8(14)-en-15-one (XII) in remarkably high (68%) yield. Dehydration of XII via the orthonitrophenylselenide to the 23-ene, followed by addition of (CF3)2CFI gave (23R)-3 beta-acetoxy-7 alpha-methyl-23-iodo-25,26,26,26,27,27,27-heptafluoro-5 alpha-cholest-8(14)-en-15-one (XV). Reductive deiodination of XV with tributyltin hydride, followed by hydrolysis of the acetate gave 3 beta-hydroxy-7 alpha-methyl-25,26,26,26,27,27,27-heptafluoro-5 alpha-cholest-8(14)-en-15-one (X). The F7-7 alpha-methyl-15-ketosterol X lowered the levels of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in CHO-K1 cells with a potency equivalent to that of I. X showed significant hypocholesterolemic action upon oral administration to rats, with a potency far in excess of the 7 alpha-methyl-15-ketosterol IX lacking the F7 substitution. In marked contrast to I, X showed little or no suppression of food consumption in rats. Upon oral administration of X to rats, low levels of X (relative to cholesterol), characterized by chromatographic and gas chromatography-mass spectrometric methodologies, were observed in serum, liver, and small intestine. No material was observed with the expected properties of F7-7-methylcholesterol (or potential intermediates in its possible formation from X). In contrast to I, X lowered serum cholesterol levels at dosages at which no effect on food consumption was observed.
Subject(s)
Anticholesteremic Agents/chemical synthesis , Cholestenones/chemical synthesis , Cholesterol/metabolism , Animals , Anticholesteremic Agents/administration & dosage , Anticholesteremic Agents/chemistry , Cells, Cultured , Cholestenones/chemistry , Diet , Magnetic Resonance Spectroscopy , Mammals , Mass Spectrometry , RatsABSTRACT
As described by Carter et al. (J. Biol. Chem. 1951. 192: 197-207), O-methyl derivatives of sphingosine are formed upon acid hydrolysis of sphingolipids in the presence of methanol. In the present study, we have isolated four O-methyl ethers of C18-sphingosine by medium pressure liquid chromatography of their diacetate derivatives, i.e., (2S,3R,4E)-1-acetoxy-2-acetamido-3-methoxy-4-octadecene, its (2S,3S) epimer, (2R,3E,5R)-1-acetoxy-2-acetamido-5-methoxy-3-octadecene, and its (2R,5S) epimer. Structures were determined by physical, chromatographic, and spectral properties. The 5-O-methyl ethers, which were the predominant byproducts of sphingolipid hydrolysis, were easily distinguished from the 3-O-methyl ethers by chromatography, and all four isomers could be differentiated by 1H and 13C nuclear magnetic resonance (NMR) spectroscopy. NMR analysis of the original N-acetate and diacetate samples of O-methylsphingosines I and II of Carter et al. demonstrated that they correspond to the 5-O-methyl ethers (2R,5R and 2R,5S, respectively), with purities of approximately 90-99%. Resolution enhancement of the 126-MHz 13C NMR spectra of the O-methyl ethers and D-erythro-C18-sphingosine (Ia) afforded distinct signals for nearly all carbon atoms. 13C NMR assignments of carbons 7-15 were made from their lanthanide-induced shifts, and revised assignments for olefinic carbons of Ia were established based upon 1H-13C shift correlation experiments.
Subject(s)
Sphingolipids/chemistry , Sphingosine/analogs & derivatives , Magnetic Resonance Spectroscopy , Sphingosine/chemistry , Sphingosine/isolation & purificationABSTRACT
3 beta-Hydroxy-25,26,26,26,27,27,27-heptafluoro-5 alpha-cholest-8(14)-en-15-one (VII), an analog of 3 beta-hydroxy-5 alpha-cholest-8(14)-en-15-one (I) in which conversion to 26- and 25-oxygenated metabolites is blocked by the F7-substitution, was administered to male Sprague-Dawley rats at levels of from 0.025 to 0.15% by weight in a ground chow diet. Administration of VII resulted in lowering of the levels of serum cholesterol at dosages as low as 0.025% by weight in diet. In marked contrast to I, VII had little or no effect on food consumption. Whereas administration of I at a level of 0.1% by weight in diet resulted in a cessation of growth, VII, at approximately the same molar concentration in diet, had only slight or no effect on changes in total body weight. Significant levels of 25,26,26,26,27,27,27-heptafluorocholesterol (VIII) were observed in serum and liver, indicating the conversion of VII to VIII. Characterization of VIII in liver was based upon the results of gas chromatography, low and high resolution mass spectral studies, infrared spectroscopy, and 1H and 13C nuclear magnetic resonance spectroscopy. The levels of VIII in serum appeared to be related to dosage and duration of administration of VII.
Subject(s)
Cholestenones/chemistry , Cholestenones/pharmacology , Sterols/antagonists & inhibitors , Animals , Body Weight , Cholestenones/administration & dosage , Cholesterol/analogs & derivatives , Cholesterol/blood , Cholesterol/isolation & purification , Cholesterol/metabolism , Chromatography, High Pressure Liquid , Colorimetry , Diet , Eating , Liver/chemistry , Male , Organ Size , Rats , Rats, Sprague-Dawley , Sterols/biosynthesis , Sterols/bloodABSTRACT
The 7 alpha-methyl analog (II) of 3 beta-hydroxy-5 alpha-cholest-8(14)-en-15- one (I) was prepared by chemical synthesis and evaluated with respect to its effects on HMG-CoA reductase activity in CHO-K1 cells and on serum cholesterol levels in rats. The 7 alpha-methyl substitution had no detectable effect on the potency of I in lowering HMG-CoA reductase activity in the cultured cells. In contrast, the 7 alpha-methyl substitution had a marked effect on the action of I in the suppression of food consumption in rats. Whereas II was less potent than I in lowering serum cholesterol levels in rats, it did so at dosage levels at which only slight or moderate effects on food consumption were observed. Full 1H and 13C-NMR assignments for II and intermediates in its synthesis have been presented. Conformational analysis, based on 1H-1H coupling constants, NMR shieldings and force-field calculations, indicated that the 7 alpha-methyl substitution had virtually no effect on the conformation of the 15-ketosterol apart from minor distortions of ring B.
Subject(s)
Cholestenones/pharmacology , Cholesterol/blood , Hydroxymethylglutaryl CoA Reductases/metabolism , Sterols/biosynthesis , Animals , Body Weight/drug effects , CHO Cells/drug effects , CHO Cells/enzymology , Cells, Cultured , Cholestenones/chemical synthesis , Cholesterol/biosynthesis , Cricetinae , Eating/drug effects , Hydroxymethylglutaryl CoA Reductases/drug effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Liver/drug effects , Liver/metabolism , Male , Organ Size/drug effects , Rats , Rats, Sprague-Dawley , Sterols/blood , Structure-Activity RelationshipABSTRACT
(25R)-26-Hydroxycholesterol (I) was synthesized in six steps from (22Z,25R)-cholesta-5,22-diene-3 beta,26-diol (II) in 31% overall yield. The 26-tert-butyldiphenylsilyl ether of II was converted via its 3 beta-tosylate to (22Z,25R)-6 beta-methoxy-26-(tert- butyldiphenylsilyloxy)-3 alpha,5-cyclo-5 alpha-cholest-22-ene (V). Removal of the 26-silyl group of V gave (22Z,25R)-6 beta-methoxy-3 alpha,5-cyclo-5 alpha-cholest-22-en-26-ol, which was hydrogenated over platinum oxide and then hydrolyzed to I. Catalytic reduction in the presence of deuterium or tritium gas gave [2H]-I or [3H]-I, respectively. Analysis of the [2H]-I by mass spectrometry showed that all the deuterium was located in the sterol side chain, mainly as d2, d3, and d4 species. The 2H and 13C nuclear magnetic resonance (NMR) spectra of [2H]-I indicated that most of the deuterium was located at C-22 and C-23, with lesser amounts at C-24 and minor amounts at C-20, C-21, C-25, and C-27. NMR spectra of [2H]-I and its alpha-methoxy-alpha-(trifluoromethyl)phenylacetate diester showed no detectable 20S epimer and approximately 2% of the 25S epimer. The [3H]-I was prepared analogously to [2H]-I using carrier-free tritium and showed a specific activity of 16.9 Ci/mmol. All synthetic intermediates were characterized fully by 1H and 13C NMR, and representative 1H-1H coupling constants are given for the ring A protons of i-steroids.
Subject(s)
Diosgenin/chemistry , Hydroxycholesterols/chemical synthesis , Deuterium , Hydroxycholesterols/chemistry , Magnetic Resonance Spectroscopy , Mass Spectrometry , Molecular Conformation , Oxidation-Reduction , TritiumABSTRACT
D-Erythro-sphingosine lowered the levels of HMG-CoA reductase activity in CHO-K1 cells. Significant suppression of reductase activity was observed at 5 microM, 10 microM, and 15 microM concentrations of the sphingolipid base and approximately 50% lowering was found at 10 microM. In contrast, L-threo-sphingosine had no effect on the levels of reductase activity under the conditions studied. Direct addition of D-erythro-sphingosine, at concentrations up to 100 microM, to rat liver microsomes had no effect on the levels of HMG-CoA reductase activity. The concentrations of D-erythro-sphingosine required to lower reductase activity in CHO-K1 cells correspond to reported levels of sphingosine in mammalian cells.
Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors , Microsomes, Liver/enzymology , Sphingosine/pharmacology , Animals , CHO Cells , Cricetinae , Dose-Response Relationship, Drug , Kinetics , Male , Rats , Rats, Sprague-Dawley , Sphingosine/chemistry , Sphingosine/isolation & purification , StereoisomerismABSTRACT
5 alpha-Cholest-8(14)-en-3 beta-ol-15-one is a potent inhibitor of cholesterol biosynthesis which has significant hypocholesterolemic activity upon oral administration to rodents and nonhuman primates. In the present study the metabolism of the 15-ketosterol has been investigated after the oral administration of a mixture of [2,4-3H]5 alpha-cholest-8(14)-en-3 beta-ol-15-one and [4-14C]cholesterol to 8 baboons. Blood samples were obtained at 4, 8, 12, 16, and 24 h after administration of the labeled sterols. Clear differences in the time courses of the levels of 3H and 14C in plasma were observed. 3H in plasma showed maximum values at 4 to 8 h, whereas maximum values for the levels of 14C were observed much later. 3H in plasma was shown to be primarily in the form of its metabolites, i.e. esters of the 15-ketosterol, cholesterol, and cholesteryl esters. The levels of the 15-ketosterol and of each of these metabolites showed different changes with time. The labeled cholesterol (and the cholesterol moiety of the cholesteryl esters), formed from the [2,4-3H]-15-ketosterol, was characterized by chromatography and by purification by way of its dibromide derivative. At 24 h after the administration of the labeled sterols, the distribution of 3H in plasma lipoprotein fractions paralleled that of 14C, with most of the 3H and 14C in high density lipoprotiens (HDL) and low density lipoproteins (LDL). Almost all of the 3H in HDL and in LDL was found as cholesterol, cholesteryl esters and esters of the 15-ketosterol. The distribution of 3H in HDL and in LDL of the free 15-ketosterol, esters of the 15-ketosterol, cholesterol, and cholesteryl esters was similar to that of plasma, thereby indicating no unusual concentration of any of the 3H labeled components in HDL or LDL.
Subject(s)
Cholestenes/metabolism , Cholestenones/metabolism , Sterols/biosynthesis , Administration, Oral , Animals , Cholestenones/administration & dosage , Cholesterol/blood , Chromatography, Liquid , Lipoproteins, HDL/blood , Lipoproteins, LDL/blood , Lipoproteins, VLDL/blood , Male , Papio , Sterols/antagonists & inhibitorsABSTRACT
The morphological effects of short-term (9 days) dietary administration (0.1% in a laboratory chow diet) of 5 alpha-cholest-8(14)-en-3 beta-ol-15-one, a novel regulator of cholesterol metabolism with significant hypocholesterolemic activity, has been studied in young male rats. Control animals included rats fed the basal diet ad libitum and a series of rats pair-fed to the individual experimental animals. At the time of necropsy, the morphological changes in rats which have been observed in rats following treatment with other absorbable hypolipidemic agents (myeloid bodies with triparanol, increased peroxisomes with clofibrate, and proliferation of smooth endoplasmic reticulum with compactin and mevinolin) were not apparent on ultrastructural examination of livers of rats treated with the 15-ketosterol. Two changes were observed in the rats fed the 15-ketosterol: a decrease in adipose tissue and enlargement of the small intestine. Diminished fat was also noted in the pair-fed controls and was presumably due to decreased food consumption. The intestines of rats fed the 15-ketosterol were morphometrically most enlarged in the jejunal region. Morphologically, this increase was distinguished by increased depth of crypts of Lieberkuhn and pseudostratification of epithelium at the base of the villi. These changes were qualitatively and quantitatively similar to the adaptive changes reported in the rat after resection of small bowel or following intestinal bypass (segment of bowel remaining in continuity). The morphological changes induced in the rat by administration of the 15-ketosterol were not observed in 4 baboons which received the compound orally at doses of 50, 75, or 100 mg per kilogram of body weight for up to 3 months.
Subject(s)
Anticholesteremic Agents/toxicity , Cholestenes/toxicity , Cholestenones/toxicity , Animals , Body Weight/drug effects , Cholesterol/blood , Diet , Eating/drug effects , Intestinal Mucosa/pathology , Intestine, Small/pathology , Male , Rats , Rats, Inbred Strains , Time FactorsABSTRACT
The metabolism of 5 alpha-cholest-8(14)-en-3 beta-ol-15-one (I), a potent regulator of cholesterol (Chol) metabolism which has significant hypocholesterolemic activity upon oral administration to animals, has been investigated in male rats. After intragastric administration of [2,4-3H] I and [4-14C]Chol in triolein to intestinal lymph duct-cannulated rats, most of the 3H of the lymph was associated with chylomicrons. Most of the 3H in the chylomicrons was associated with fatty acid esters of I and the oleate ester represented the major species of the esters of I. After intravenous injection of the isolated doubly-labeled chylomicrons to intact rats, rapid clearance of 3H and 14C from blood was observed which was associated with a rapid and selective uptake of 3H and 14C by liver. The rate of disappearance of 3H from blood and the rate of uptake of 3H by liver were similar, if not identical, to those for 14C. In contrast, the disappearance of 3H from the liver was much more rapid than that of 14C. Studies of the distribution of 3H in liver demonstrated rapid formation of free I and the formation of [3H]Chol. In addition, significant amounts of the 3H in liver were associated with polar materials, a finding which was not observed in the case of 14C. After intravenous administration of the doubly-labeled chylomicrons to bile duct-cannulated rats, very rapid and substantial metabolism of the administered 3H to polar biliary metabolites was observed. The bulk of the 3H not recovered in bile at 49 h after the injection of the labeled chylomicrons was recovered in blood and tissues and almost all (integral of 94%) of this material was associated with Chol and Chol esters. The combined results indicate an important role for chylomicrons in the overall metabolism of I. The selective delivery of I to liver as its oleate ester in chylomicrons (or, more probably, as chylomicron remnants) and the subsequent metabolism of the oleate ester of I in liver has important consequences with respect to the actions of I which are discussed herein.
Subject(s)
Anticholesteremic Agents/metabolism , Cholestenes/metabolism , Cholestenones/metabolism , Chylomicrons/physiology , Sterols/biosynthesis , Animals , Bile/metabolism , Cholesterol/metabolism , Chylomicrons/isolation & purification , Intestines/analysis , Liver/metabolism , Lymph/analysis , Male , Rats , Rats, Inbred StrainsABSTRACT
A four-step synthesis of 3 beta-hydroxy-5 alpha-cholest-8(14)-en-15-one (I) from 7-dehydrocholesterol is described. This synthesis, which is efficient and suitable for kilogram scale work, was carried out in a 33% overall average yield (39% overall best yield). A major byproduct of the hydrolysis of 3 beta-benzoyloxy-14 alpha,15 alpha-epoxy-5 alpha-cholest-7-ene to I was found to be the ring C aromatic sterol 12-methyl-18-nor-5 alpha-cholesta-8,11,13-trien-3 beta-ol. Several other intermediates and byproducts of these reactions were also identified. All new sterols were characterized by 1H- and 13C-NMR.
Subject(s)
Cholestenes/chemical synthesis , Cholestenones/chemical synthesis , Cholesterol/metabolism , Cholestenes/metabolism , Hydrolysis , Magnetic Resonance Spectroscopy , Norsteroids/chemical synthesisABSTRACT
The metabolism of 5 alpha-cholest-8(14)-en-3 beta-ol-15-one, a potent inhibitor of cholesterol synthesis with marked hypocholesterolemic activity, has been studied after the intravenous administration of a mixture of [2,4-3H]5 alpha-cholest-8(14)-en-3 beta-ol-15-one and [4-14C] cholesterol to a baboon. The levels of 3H in plasma which was associated with the free 15-ketosterol decreased very rapidly (T1/2 approximately 9 min) after injection of the labeled sterol. By 4 h, the level of the [3H]15-ketosterol in plasma was negligible. The rapid decrease in the levels of the free 15-ketosterol was associated with rapid formation of fatty acid esters of the 15-ketosterol. The maximum level of 3H-labeled 15-ketosteryl esters was observed at 20 min after the injection of the 15-ketosterol. Thereafter, the levels of the 15-ketosteryl esters decreased rapidly with an apparent T1/2 of approximately 3.5-4.0 h. The results also indicated rapid formation of 3H-labeled cholesterol and cholesteryl esters. Substantial formation of [3H]cholesterol was observed at 20 min after the injection of the 15-ketosterol and reached a maximum level in plasma at 2 h. The maximum levels of [3H]cholesteryl esters in plasma were observed much later. These and other findings indicated that the observed slow clearance of total 3H from plasma is a consequence of metabolism of the 15-ketosterol to cholesterol and cholesteryl esters, normal constituents of plasma whose turnover in the whole animal is known to be relatively slow.
Subject(s)
Anticholesteremic Agents/pharmacology , Cholestenes/metabolism , Cholestenones/metabolism , Cholesterol/biosynthesis , Papio/metabolism , Animals , Cholesterol Esters/metabolism , Chromatography, High Pressure Liquid , Half-Life , Male , Reference Values , Time FactorsABSTRACT
The metabolism of 5 alpha-cholest-8(14)-en-3 beta-ol-15-one has been studied after intravenous administration to bile duct-cannulated rats. Very rapid and substantial conversion of the 15-ketosterol to polar biliary metabolites was observed in both male and female rats. For example, upon intravenous injection of [4-14C]5 alpha-cholest-8(14)-en-3 beta-ol-15-one to male bile duct-cannulated rats, approximately 86% of the administered 14C was recovered in bile in the first 38 h. Of the total amount of 14C recovered in bile in 38 h, approximately 50% was excreted in bile in the first 70 min and approximately 90% was excreted within 8 h after the injection of the 15-ketosterol. A substantial fraction of the polar biliary metabolites was shown to undergo enterohepatic circulation. Of the radioactivity derived from the labeled 15-ketosterol which was not recovered in bile or other excreta at 48 h after the intravenous administration of the 15-ketosterol, most (approximately 79%) was recovered in the form of cholesterol and cholesteryl esters of blood and the various tissues. The very substantial and rapid biliary excretion of polar metabolites of the 15-ketosterol (or of cholesterol derived from the 15-ketosterol), coupled with inhibition of the intestinal absorption of cholesterol by the 15-ketosterol, may contribute to the overall hypocholesterolemic action of the 15-ketosterol which has been observed in rodents and in nonhuman primates by providing a metabolic pathway(s) wherein a substantial fraction of the absorbed 15-ketosterol is rapidly removed from the body by biliary excretion in the form of polar metabolites.
Subject(s)
Cholestenes/metabolism , Cholestenones/metabolism , Cholesterol/biosynthesis , Animals , Bile/metabolism , Bile Ducts , Catheterization , Duodenum , Female , Injections, Intravenous , Male , Rats , Splanchnic CirculationABSTRACT
Dietary administration (0.1% in a chow diet for 8 days) of 5 alpha-cholest-8(14)-en-3 beta-ol-15-one, a potent inhibitor of sterol biosynthesis with marked hypocholesterolemic action, to rats caused a 77% reduction in the levels of acyl co-enzyme A:cholesterol acyl transferase activity of jejunal microsomes relative to those observed in pair-fed control animals. No differences were observed in mean levels of cholesterol concentration in jejunal microsomes of experimental and pair-fed control animals.
Subject(s)
Cholestenes/pharmacology , Cholestenones/pharmacology , Sterol O-Acyltransferase/antagonists & inhibitors , Sterols/biosynthesis , Animals , Cholesterol/metabolism , Dietary Fats/pharmacology , Intestinal Absorption , Jejunum/enzymology , Male , Microsomes/enzymology , RatsABSTRACT
The effect of 5 alpha-cholest-8(14)-en-3 beta-ol-15-one, a potent inhibitor of cholesterol synthesis with marked hypocholesterolemic activity, on the intestinal absorption of exogenous cholesterol has been studied in lymph-cannulated rats. Administration of the 15-ketosterol at a level of 0.05% in a rat chow diet for 10 days was associated with a marked decrease (-64%) in the absorption of cholesterol.
Subject(s)
Anticholesteremic Agents/pharmacology , Cholestenes/pharmacology , Cholestenones/pharmacology , Cholesterol/metabolism , Intestinal Absorption/drug effects , Lymph/physiology , Animals , Body Weight/drug effects , Eating/drug effects , Kinetics , Male , Rats , Rats, Inbred StrainsABSTRACT
The metabolism of 5 alpha-cholest-8(14)-en-3 beta-ol-15-one (I), a potent inhibitor of cholesterol synthesis with marked hypocholesteremic activity, has been studied in a nonhuman primate. A mixture of [2,4-3H]-I and [4-14C]-cholesterol was administered to a male baboon in the form of a feedball. Blood was samples at 4, 8, 12, 16, and 24 hr. Detailed analyses of the plasma lipids indicated very rapid absorption of I (relative to cholesterol) and metabolism to cholesterol, cholesteryl esters, and esters of I. The labeled cholesterol was characterized by chromatographic techniques and by purification by way of its dibromide derivative. The levels of 3H in plasma associated with I, esters of I, cholesterol, and cholesteryl esters each showed a different time course. By 24 hr after the administration of [2,4-3H]-I, most of the 3H in plasma was associated with cholesterol and cholesteryl esters. The levels of total 3H and 14C in plasma at various times after the administration of the mixture of [2,4-3H]-I and [4-14C]-cholesterol differed markedly with 3H showing a maximum value at 4 hr and 14C showing a maximum value at 24 hr.
Subject(s)
Anticholesteremic Agents/blood , Cholestenes/blood , Cholestenones/blood , Cholesterol/blood , Administration, Oral , Animals , Biotransformation , Carbon Radioisotopes , Cholestenones/administration & dosage , Kinetics , Male , Papio , TritiumABSTRACT
5 alpha-Cholest-8(14)-en-3 beta-ol-15-one has been found to have significant hypocholesterolemic activity upon oral administration at a daily dosage of 75 mg/kg of body weight to Rhesus monkeys fed a diet of moderate cholesterol (Chol) content [0.19 mg/kcal (1 cal = 4.184 J) of diet]. The reductions in total serum Chol levels (mean, -41%) were associated with even more striking reductions (mean, -61%) in the levels of low density lipoprotein (LDL) plus very low density lipoprotein (VLDL) Chol and also with increases in high density lipoprotein (HDL) Chol levels (mean, +61%). The mean increase in HDL Chol was 33 mg/dl. In one animal, that with the lowest pretreatment HDL Chol level, the extent of the rise was 49 mg/dl (+120%). These changes were associated with reductions in the % of total serum Chol associated with LDL/VLDL, in the ratios of total Chol to HDL Chol and of LDL/VLDL Chol to HDL Chol, and in the levels of LDL protein. The 15-ketosterol also increased the % of total Chol associated with HDL, increased the level of HDL protein, and induced a shift in the HDL profile to one in which the HDL2 species was the predominant species. All of these changes are those generally considered desirable for the treatment and/or prevention of atherosclerosis.
Subject(s)
Cholestenes/pharmacology , Cholestenones/pharmacology , Cholesterol, Dietary/administration & dosage , Cholesterol/blood , Lipoproteins/blood , Animals , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Cholesterol, VLDL , Kinetics , Lipoproteins, VLDL/blood , Macaca mulatta , Male , Triglycerides/bloodABSTRACT
5 alpha-Cholest-8(14)-en-3 beta-0l-15-one has been found to have significant hypocholesterolemic action on oral administration to baboons at dosages of 50 and 75 mg/kg of body weight. The 15-ketosterol decreased the levels of total serum cholesterol and low density lipoprotein plus very low density lipoprotein (LDL/VLDL) cholesterol and the percentage of total cholesterol associated with LDL/VLDL and increased the percentage of total cholesterol associated with high density lipoprotein (HDL). Moreover, administration of the steroid was associated with an absolute increase in the concentration of HDL cholesterol in those animals with low HDL levels (or with a low percentage of total serum cholesterol in the HDL fraction.
Subject(s)
Anticholesteremic Agents , Cholestenes/pharmacology , Cholestenones/pharmacology , Cholesterol/blood , Lipoproteins/metabolism , Animals , Male , PapioABSTRACT
A relatively simple method is described for the isolation of zymosterol (5 alpha-cholesta-8, 24-dien-3 beta-ol) of high purity from baker's yeast. Also presented are detailed spectral properties, including 13C NMR spectral analyses, of zymosterol and its acetate derivative.